NCT03577886View on ClinicalTrials.gov

Safety and Tolerability of CDX-6114 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 4, 2018

Primary Completion Date

August 21, 2018

Study Completion Date

September 4, 2018

Conditions
Healthy
Interventions
DRUG

CDX-6114

CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.

DRUG

Placebo

Phosphate Buffer Diluent oral solution

Trial Locations (1)

6009

Linear Clinical Services, Perth

Sponsors

Lead Sponsor

Codexis Inc.
All Listed Sponsors
lead

Codexis Inc.

INDUSTRY

NCT03577886 - Safety and Tolerability of CDX-6114 in Healthy Volunteers | Biotech Hunter | Biotech Hunter